Chris Carpenter has more than two decades of clinical and laboratory experience in oncology. He focuses on clinical-stage product companies, particularly in oncology, rare diseases, and other specialty therapeutic areas.
Before joining Sofinnova in 2022, Chris was Chief Medical Officer at CatamaranBio. Previously, he was the Chief Medical Officer at Rubius Therapeutics, a company developing red blood cells as therapeutics. Prior to Rubius, Chris was Senior Vice President and Head of the Cancer Epigenetics group at GlaxoSmithKline, where he was responsible for the overall strategy, as well as the identification and validation of new epigenetic targets and advancing novel therapies through clinical proof of concept. While at GlaxoSmithKline, Chris also led the development of Votrient (pazopanib). Before GlaxoSmithKline, he was at Merck and led the development of MK-4827, which became Tesaro’s Zejula. Prior to Merck, Chris led a laboratory at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in internal medicine and medical oncology.
Chris earned his B.S. from Stanford University, and received his M.D. and Ph.D. (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.